KPW
PTGX icon

Kore Private Wealth’s Protagonist Therapeutics PTGX Stock Holding History

Kore Private Wealth’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-500
Closed -$8K – 873
2020
Q2 		$8K Hold
500
– – ﹤0.01% 836
2020
Q1 		$4K Hold
500
– – ﹤0.01% 847
2019
Q4 		$4K Buy
+500
New +$4.96K ﹤0.01% 885
2019
Q2 		– Sell
-1,000
Closed -$13K – 644
2019
Q1 		$13K Hold
1,000
– – ﹤0.01% 568
2018
Q4 		$7K Buy
+1,000
New +$7.93K ﹤0.01% 627

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Kore Private Wealth's PTGX Position: Q3 2020 in Review

Kore Private Wealth sold out of Protagonist Therapeutics (PTGX) in Q3 2020, closing a stake of 500 shares — an estimated $8K sold.

Kore Private Wealth first reported a position in PTGX in Q4 2018 and held it in 5 quarters. The position peaked at $13K in Q1 2019. 92 funds tracked by Wall St. Rank hold PTGX as of Q3 2020.

  • Kore Private Wealth reported no remaining Protagonist Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Kore Private Wealth sold 500 Protagonist Therapeutics shares in Q3 2020, an estimated $8K.
  • Kore Private Wealth first reported a position in Protagonist Therapeutics in Q4 2018 and held it in 5 quarters.
  • Kore Private Wealth's Protagonist Therapeutics position peaked at $13K in Q1 2019.
  • 92 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2020.

Based on Kore Private Wealth's 13F filing for Q3 2020, filed 13 Nov 2020.